Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.48 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 5/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3308443 | 0.90 | MAPT (0.59) | MAPTRIPK1CYP11B1CYP11B2SLC13A5 | |
| SCHEMBL3306622 | 0.84 | CYP11B1 (0.46) | MAPTCYP11B1CYP11B2SLC13A5HRH3 | |
| SCHEMBL3308922 | 0.82 | CYP11B1 (0.47) | CYP11B1CYP11B2HRH3CYP1A2 | |
| SCHEMBL3306023 | 0.81 | MEN1 (0.45) | MAPTCYP11B1CYP11B2FFAR1FFAR4 | |
| SCHEMBL3306413 | 0.81 | KIF11 (0.44) | MAPTCYP11B1CYP11B2HRH3CYP1A2 | |
| SCHEMBL3309131 | 0.81 | MAPT (0.58) | MAPTRIPK1CYP11B1CYP11B2HRH3 | |
| SCHEMBL12674687 | 0.80 | MAPT (0.48) | MAPTHRH3DHODHFFAR1FFAR4 | |
| SCHEMBL3307032 | 0.80 | CYP11B1 (0.47) | CYP11B1CYP11B2CYP1A2USP30 | |
| SCHEMBL3309801 | 0.78 | CYP11B1 (0.44) | MAPTCYP11B1CYP11B2CYP1A2 | |
| SCHEMBL3310060 | 0.77 | CYP11B1 (0.44) | MAPTCYP11B1CYP11B2HRH3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952007-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-02-10 | — | — | US | claimed |
| US-20130096122-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2013-04-18 | — | — | US | claimed |
| US-20100113514-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | claimed |
| US-8952007-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8664379-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130096122-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20100113514-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113514-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, KCNH3 | MAPT 3423/4885RIPK1 1080/4885CYP11B1 1655/4885 |
| US-20130096122-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, CACNA1E | MAPT 3659/4885RIPK1 1310/4885CYP11B1 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.